Emmanuel Bachy

Emmanuel Bachy

Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 194 publications

CAR in R/R FL: is real-world efficacy meeting expectations?

CAR in R/R FL: is real-world efficacy meeting expectations?

Journal: Blood advances

Published: May 29, 2026

Marginal Zone Lymphoma With T-Follicular Helper Hyperplasia: Paving the Way for New Concepts in Cellular Plasticity and Unveiling Histopathologic Pitfalls.

Marginal Zone Lymphoma With T-Follicular Helper Hyperplasia: Paving the Way for New Concepts in Cellular Plasticity and Unveiling Histopathologic Pitfalls.

Journal: The American journal of surgical pathology

Published: May 14, 2026

Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.

Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.

Journal: Bone marrow transplantation

Published: March 09, 2026

Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma.

Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma.

Journal: Leukemia & lymphoma

Published: February 25, 2026

Oncogenic Role of BCL6 Rearrangement: A Focus on Follicular and Marignal Zone Lymphomas.

Oncogenic Role of BCL6 Rearrangement: A Focus on Follicular and Marignal Zone Lymphomas.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: February 09, 2026

Nodal T-follicular helper cell lymphoma with clonal B-cell component: a distinct mutational profile and aggressive clinical behavior.

Nodal T-follicular helper cell lymphoma with clonal B-cell component: a distinct mutational profile and aggressive clinical behavior.

Journal: Leukemia & lymphoma

Published: January 29, 2026

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Journal: Immuno-oncology technology

Published: January 08, 2026

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Journal: Immuno-oncology technology

Published: January 08, 2026

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 02, 2025

Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.

Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.

Journal: Leukemia

Published: November 20, 2025

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 16, 2025

Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.

Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.

Journal: Blood advances

Published: August 11, 2025

Showing 1-12 of 194

Last Updated: 09/26/2026